-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
*Only for medical professionals to read and refer to the light of domestically developed anti-cancer: The real world study results of Fruquintinib for third-line and later treatment of Chinese patients with metastatic colorectal cancer have been announced
.
In recent years, with the continuous advancement of medical diagnosis and treatment, treatment methods for patients with metastatic colorectal cancer (mCRC) have become more diverse
.
In addition to traditional radiotherapy and chemotherapy models, targeted and immunotherapy have also ushered in more and better treatment options for mCRC patients
.
Currently, immunotherapy has been approved for the first-line treatment of advanced CRC with highly unstable microsatellites (MSI-H) or mismatch repair gene defects (dMMR)
.
At the 24th Chinese Society of Clinical Oncology (CSCO) Annual Conference, a real-world study on the effectiveness of tyrosine kinase inhibitors (TKI) for the third-line and later treatment of Chinese patients with metastatic colorectal cancer The results are announced
.
To this end, the "medical community" specially invited Professor Jin Ying from Sun Yat-sen University Cancer Center to conduct research presentations, and Professor Zhang Yanqiao from the Cancer Hospital of Harbin Medical University to comment on the research and share the current status of mCRC treatment
.
Facing difficulties-China's third-line treatment of colorectal cancer is densely covered with thorns.
Colorectal cancer is one of the three most common malignant tumors in China.
According to the latest global cancer burden data released by the International Agency for Research on Cancer (IARC) of the World Health Organization: 2020 There are about 555,000 new cases of CRC in China, accounting for 12.
2% of the number of newly diagnosed cancers in China that year
.
There were 286,000 deaths, accounting for 9.
5% of China’s cancer deaths that year
.
And 83% of CRC patients are in the middle and late stage at the time of diagnosis [1], and treatment is more difficult
.
What is the basic situation of the current third-line treatment of mCRC patients in my country? Professor Zhang Yanqiao said: “Intestinal cancer is different from gastric cancer.
After standard first-line and second-line treatment, many patients can get a relatively long survival time and have the opportunity to use third-line and later drug treatment
.
But in general, the third-line and later treatment The curative effect is not ideal
.
” And the dilemma of mCRC patients receiving back-line treatment is not only that, Professor Zhang Yanqiao also said: “Not every patient has the opportunity to use third-line treatment drugs, for example, the patient’s genetic test is not MSI-H or dMMR.
It may not be possible to benefit from PD-1 monoclonal antibody treatment
.
We hope to find opportunities for genetically tested microsatellite stable (MSS) colorectal cancer patients to benefit from immunotherapy
.
At the same time, we also want to understand the real world , mCRC patients with the use of third-line treatment drug efficacy exactly how
.
based on this, we have designed and promoted the three-line and real-world studies about the effectiveness of TKI drugs for future treatment of patients with mCRC
.
"down to earth - furosemide quinoline imatinib third-line treatment outcome research in the real world Encouraging In 2017 and 2018, regorafenib and fruquintinib, two multi-targeted TKIs, were approved by the National Medical Products Administration as the third-line and later drugs for advanced CRC
.
"Although fruquintinib and regorafenib have been approved for clinical use, how effective are different TKI drugs in real-world applications? Are there differences? There are few relevant reports
.
Therefore, we conduct real-world research.
To understand the use data of real-world TKI drugs in mCRC patients can provide reference for clinicians’ medication use
.
" Professor Jin Ying said in an interview
.
This study summarizes the clinical data of a total of 156 patients with multi-target TKI third-line treatment of mCRC in 6 tertiary hospitals in China from July 2014 to February 2020.
Among them, 41 cases were treated with fruquintinib.
Another 115 patients received regorafenib treatment
.
The primary endpoints of the study are progression-free survival (PFS) and overall survival (OS)
.
The results of the study showed that fruquintinib has a clear advantage over regorafenib in the third-line treatment of mCRC patients.
Professor Jin Ying explained the research data in detail: "The median progression-free survival (mPFS) of the regorafenib treatment group is 2.
4 Compared with the previous month, the mPFS of the fruquintinib group was significantly prolonged to 4.
0 months
.
For
patients who have previously used anti-VEGF antibodies or have liver metastases, the results of the study show that the use of fruquintinib has a greater survival benefit
.
" The real-world study announced that there is a significant difference in the efficacy of fruquintinib and regorafenib in patients with mCRC, which will provide a strong evidence-based basis for the choice of third-line treatment for clinical mCRC patients
.
Challenge the dilemma-the treatment of metastatic colorectal cancer, fruquintinib lives up to expectations.
Fruquintinib, as a TKI drug approved for the third-line treatment of mCRC, has an eye-catching performance in this real-world study, which will benefit clinical mCRC patients What are the positive effects of treatment? Professor Jin Ying said: “Research data shows that among the mCRC patients in China, the third-line and subsequent treatments of Fruquintinib get longer mPFS than the patients with Regorafenib
.
This real-world study can be used by clinicians.
Choosing to provide evidence-based medicine for data reference will be very meaningful
.
” Professor Zhang Yanqiao said when talking about the experience of using Fruquintinib and Regorafenib: “Whether it is based on the results of this real-world study or According to the observation of clinical patients' use, Fruquintinib has shown good efficacy and safety
.
Especially for patients with poor general conditions, choosing Fruquintinib as a single-agent therapy may bring PFS benefits.
After Fruquintinib is listed, many professors have received unanimous praise
.
"Looking to the future-Fruquintinib of Sinopharm brings new hope.
Although immunotherapy has achieved breakthrough effects in MSI-H/dMMR mCRC patients, for the other 95% of MSS patients, single-agent immunotherapy has limited efficacy.
How to extend it Its survival period has become a clinical difficulty
.
What are the
future directions for the future treatment of mCRC patients? Professor Zhang Yanqiao said: "In clinical practice, both doctors and patients are full of expectations for immunotherapy, because the proportion of patients with CRC MSI-H is about Only 5%, which means that 95% of patients with bowel cancer cannot benefit significantly from immunotherapy
.
We have also observed that in these 95% of patients, about 5% of the use of anti-angiogenic drugs combined with PD-1 monoclonal antibody can be observed to significantly benefit
.
In the future, if we can find out the reasons for the benefit of PD-1 monoclonal antibody combined with anti-angiogenic drugs for these patients with MSS bowel cancer, it will allow more patients to obtain treatment opportunities, which is of great significance
.
"This time, the performance of the original Chinese anti-cancer drug Fruquintinib is exciting.
When asked at the end of the interview how to better play the role of Fruquintinib in the future, Professor Zhang Yanqiao said: "Fruquintinib is a Chinese enterprise Successful cases in the medical field indicate that Chinese original research drugs have not only succeeded in clinical research, but also have been widely recognized internationally in the field of tumor treatment
.
In the future, more fruquintinib can be considered to participate in the combined treatment plan to study its feasibility, effectiveness and safety
.
Bring benefits to more mCRC patients
.
"Introduction of the guest Dr.
Ying Jin, Doctor of Medical Oncology, Sun Yat-sen University Cancer Hospital, Associate Chief Physician, Master Supervisor, CSCO Oncology Big Data Expert Committee Member, Guangdong Anti-Cancer Association Targeted and Individualized Therapy Committee Youth Committee Standing Committee Member, Guangdong Provincial Primary Medicine Association Oncology Multidisciplinary Comprehensive Diagnosis and Treatment Professional Committee Standing Committee Member of the Precision Professional Committee Member of the Youth Committee of the Colorectal Cancer Professional Committee of the Guangdong Anti-Cancer Association Member of the Oncology Professional Committee of the Guangdong Medical Education Association Member of the Digestive Tumor Youth Committee of the Guangzhou Anti-Cancer Association 2019 CSCO Colorectal Cancer MDT The champion team members of the 2019 Chinese Medical Association National Radiology Conference.
The champion team members of the Shadow Voyager MDT Case Challenge of the Chinese Medical Association published many SCI papers.
Comment on academic journals such as Mol Cancer, Br J Cancer, J TRANSL MED, JAMA ONCOL, etc.
Guest Professor Yanqiao Zhang Chief Physician, Doctoral Supervisor, Deputy Dean, Heilongjiang Cancer Center, Heilongjiang Cancer Center, Harbin Medical University, Deputy Director, Heilongjiang Gastrointestinal Tumor Diagnosis and Treatment Center, Director, Cancer Big Data and Real World Research Committee, Chinese Anti-Cancer Association Chairman, Chinese Anti-Cancer Association Cancer Drug Clinic Vice Chairman of the Research Professional Committee Vice Chairman of the CSCO Colorectal Cancer Committee Vice Chairman of the Professional Committee Member of the Standing Committee of the Gastric Cancer Professional Committee of the Chinese Anti-Cancer Association Professional Committee Standing Committee Member of the Chinese Anti-Cancer Association References: [1] The latest global cancer burden data released by the International Agency for Research on Cancer (IARC) of the World Health Organization in 2020; https://iarc.
who.
int; *This article is for use only Providing scientific information to medical professionals does not represent the views of this platform
.
In recent years, with the continuous advancement of medical diagnosis and treatment, treatment methods for patients with metastatic colorectal cancer (mCRC) have become more diverse
.
In addition to traditional radiotherapy and chemotherapy models, targeted and immunotherapy have also ushered in more and better treatment options for mCRC patients
.
Currently, immunotherapy has been approved for the first-line treatment of advanced CRC with highly unstable microsatellites (MSI-H) or mismatch repair gene defects (dMMR)
.
At the 24th Chinese Society of Clinical Oncology (CSCO) Annual Conference, a real-world study on the effectiveness of tyrosine kinase inhibitors (TKI) for the third-line and later treatment of Chinese patients with metastatic colorectal cancer The results are announced
.
To this end, the "medical community" specially invited Professor Jin Ying from Sun Yat-sen University Cancer Center to conduct research presentations, and Professor Zhang Yanqiao from the Cancer Hospital of Harbin Medical University to comment on the research and share the current status of mCRC treatment
.
Facing difficulties-China's third-line treatment of colorectal cancer is densely covered with thorns.
Colorectal cancer is one of the three most common malignant tumors in China.
According to the latest global cancer burden data released by the International Agency for Research on Cancer (IARC) of the World Health Organization: 2020 There are about 555,000 new cases of CRC in China, accounting for 12.
2% of the number of newly diagnosed cancers in China that year
.
There were 286,000 deaths, accounting for 9.
5% of China’s cancer deaths that year
.
And 83% of CRC patients are in the middle and late stage at the time of diagnosis [1], and treatment is more difficult
.
What is the basic situation of the current third-line treatment of mCRC patients in my country? Professor Zhang Yanqiao said: “Intestinal cancer is different from gastric cancer.
After standard first-line and second-line treatment, many patients can get a relatively long survival time and have the opportunity to use third-line and later drug treatment
.
But in general, the third-line and later treatment The curative effect is not ideal
.
” And the dilemma of mCRC patients receiving back-line treatment is not only that, Professor Zhang Yanqiao also said: “Not every patient has the opportunity to use third-line treatment drugs, for example, the patient’s genetic test is not MSI-H or dMMR.
It may not be possible to benefit from PD-1 monoclonal antibody treatment
.
We hope to find opportunities for genetically tested microsatellite stable (MSS) colorectal cancer patients to benefit from immunotherapy
.
At the same time, we also want to understand the real world , mCRC patients with the use of third-line treatment drug efficacy exactly how
.
based on this, we have designed and promoted the three-line and real-world studies about the effectiveness of TKI drugs for future treatment of patients with mCRC
.
"down to earth - furosemide quinoline imatinib third-line treatment outcome research in the real world Encouraging In 2017 and 2018, regorafenib and fruquintinib, two multi-targeted TKIs, were approved by the National Medical Products Administration as the third-line and later drugs for advanced CRC
.
"Although fruquintinib and regorafenib have been approved for clinical use, how effective are different TKI drugs in real-world applications? Are there differences? There are few relevant reports
.
Therefore, we conduct real-world research.
To understand the use data of real-world TKI drugs in mCRC patients can provide reference for clinicians’ medication use
.
" Professor Jin Ying said in an interview
.
This study summarizes the clinical data of a total of 156 patients with multi-target TKI third-line treatment of mCRC in 6 tertiary hospitals in China from July 2014 to February 2020.
Among them, 41 cases were treated with fruquintinib.
Another 115 patients received regorafenib treatment
.
The primary endpoints of the study are progression-free survival (PFS) and overall survival (OS)
.
The results of the study showed that fruquintinib has a clear advantage over regorafenib in the third-line treatment of mCRC patients.
Professor Jin Ying explained the research data in detail: "The median progression-free survival (mPFS) of the regorafenib treatment group is 2.
4 Compared with the previous month, the mPFS of the fruquintinib group was significantly prolonged to 4.
0 months
.
For
patients who have previously used anti-VEGF antibodies or have liver metastases, the results of the study show that the use of fruquintinib has a greater survival benefit
.
" The real-world study announced that there is a significant difference in the efficacy of fruquintinib and regorafenib in patients with mCRC, which will provide a strong evidence-based basis for the choice of third-line treatment for clinical mCRC patients
.
Challenge the dilemma-the treatment of metastatic colorectal cancer, fruquintinib lives up to expectations.
Fruquintinib, as a TKI drug approved for the third-line treatment of mCRC, has an eye-catching performance in this real-world study, which will benefit clinical mCRC patients What are the positive effects of treatment? Professor Jin Ying said: “Research data shows that among the mCRC patients in China, the third-line and subsequent treatments of Fruquintinib get longer mPFS than the patients with Regorafenib
.
This real-world study can be used by clinicians.
Choosing to provide evidence-based medicine for data reference will be very meaningful
.
” Professor Zhang Yanqiao said when talking about the experience of using Fruquintinib and Regorafenib: “Whether it is based on the results of this real-world study or According to the observation of clinical patients' use, Fruquintinib has shown good efficacy and safety
.
Especially for patients with poor general conditions, choosing Fruquintinib as a single-agent therapy may bring PFS benefits.
After Fruquintinib is listed, many professors have received unanimous praise
.
"Looking to the future-Fruquintinib of Sinopharm brings new hope.
Although immunotherapy has achieved breakthrough effects in MSI-H/dMMR mCRC patients, for the other 95% of MSS patients, single-agent immunotherapy has limited efficacy.
How to extend it Its survival period has become a clinical difficulty
.
What are the
future directions for the future treatment of mCRC patients? Professor Zhang Yanqiao said: "In clinical practice, both doctors and patients are full of expectations for immunotherapy, because the proportion of patients with CRC MSI-H is about Only 5%, which means that 95% of patients with bowel cancer cannot benefit significantly from immunotherapy
.
We have also observed that in these 95% of patients, about 5% of the use of anti-angiogenic drugs combined with PD-1 monoclonal antibody can be observed to significantly benefit
.
In the future, if we can find out the reasons for the benefit of PD-1 monoclonal antibody combined with anti-angiogenic drugs for these patients with MSS bowel cancer, it will allow more patients to obtain treatment opportunities, which is of great significance
.
"This time, the performance of the original Chinese anti-cancer drug Fruquintinib is exciting.
When asked at the end of the interview how to better play the role of Fruquintinib in the future, Professor Zhang Yanqiao said: "Fruquintinib is a Chinese enterprise Successful cases in the medical field indicate that Chinese original research drugs have not only succeeded in clinical research, but also have been widely recognized internationally in the field of tumor treatment
.
In the future, more fruquintinib can be considered to participate in the combined treatment plan to study its feasibility, effectiveness and safety
.
Bring benefits to more mCRC patients
.
"Introduction of the guest Dr.
Ying Jin, Doctor of Medical Oncology, Sun Yat-sen University Cancer Hospital, Associate Chief Physician, Master Supervisor, CSCO Oncology Big Data Expert Committee Member, Guangdong Anti-Cancer Association Targeted and Individualized Therapy Committee Youth Committee Standing Committee Member, Guangdong Provincial Primary Medicine Association Oncology Multidisciplinary Comprehensive Diagnosis and Treatment Professional Committee Standing Committee Member of the Precision Professional Committee Member of the Youth Committee of the Colorectal Cancer Professional Committee of the Guangdong Anti-Cancer Association Member of the Oncology Professional Committee of the Guangdong Medical Education Association Member of the Digestive Tumor Youth Committee of the Guangzhou Anti-Cancer Association 2019 CSCO Colorectal Cancer MDT The champion team members of the 2019 Chinese Medical Association National Radiology Conference.
The champion team members of the Shadow Voyager MDT Case Challenge of the Chinese Medical Association published many SCI papers.
Comment on academic journals such as Mol Cancer, Br J Cancer, J TRANSL MED, JAMA ONCOL, etc.
Guest Professor Yanqiao Zhang Chief Physician, Doctoral Supervisor, Deputy Dean, Heilongjiang Cancer Center, Heilongjiang Cancer Center, Harbin Medical University, Deputy Director, Heilongjiang Gastrointestinal Tumor Diagnosis and Treatment Center, Director, Cancer Big Data and Real World Research Committee, Chinese Anti-Cancer Association Chairman, Chinese Anti-Cancer Association Cancer Drug Clinic Vice Chairman of the Research Professional Committee Vice Chairman of the CSCO Colorectal Cancer Committee Vice Chairman of the Professional Committee Member of the Standing Committee of the Gastric Cancer Professional Committee of the Chinese Anti-Cancer Association Professional Committee Standing Committee Member of the Chinese Anti-Cancer Association References: [1] The latest global cancer burden data released by the International Agency for Research on Cancer (IARC) of the World Health Organization in 2020; https://iarc.
who.
int; *This article is for use only Providing scientific information to medical professionals does not represent the views of this platform
